JBTDRC
SEVAMED
Advanced Search
.
 Sevamed Home
__________________
 Recent Issue
__________________
 Diseases Covered
__________________
 Feedback
__________________
 Users Response
__________________
 Archieves
__________________
 Download
__________________
 Contact Us
__________________
Items 1 - 10 of 12

:
PMID: 28506229
Bracho-Churio YT, Martínez-Vega RA, Rodriguez-Morales AJ, Díaz-Quijano RG,Luna-González ML, Diaz-Quijano FA. Determinants of felt demand for dengue vaccines in the North Caribbean region of Colombia. Ann Clin Microbiol Antimicrob. 2017 May 15;16(1):38.
:
PMID: 27905832
Harapan H, Fajar JK, Sasmono RT, Kuch U. Dengue vaccine acceptance andwillingness to pay. Hum Vaccin Immunother. 2017 Apr 3;13(4):786-790.
:
PMID: 28067718
Melo FIR, Morales JJR, De Los Santos AHM, Rivas E, Vigne C, Noriega F.Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial. Pediatr Infect Dis J. 2017 Jun;36(6):602-608.
:
PMID: 28719287
Schmidt AC, Lin L, Martinez LJ, Ruck RC, Eckels KH, Collard A, De La BarreraR, Paolino KM, Toussaint JF, Lepine E, Innis BL, Jarman RG, Thomas SJ. Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States. Am J Trop Med Hyg. 2017 Jun;96(6):1325-1337.
:
PMID: 28500811
Shim E. Cost-Effectiveness of Dengue Vaccination Programs in Brazil. Am J TropMed Hyg. 2017 May;96(5):1227-1234.
:
PMID: 28281864
Torresi J, Ebert G, Pellegrini M. Vaccines licensed and in clinical trials forthe prevention of dengue. Hum Vaccin Immunother. 2017 May 4;13(5):1059-1072.
:
PMID: 28393307
Valdés I, Marcos E, Suzarte E, Pérez Y, Brown E, Lazo L, Cobas K, Yaugel M,Rodríguez Y, Gil L, Guillén G, Hermida L. A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses. Arch Virol. 2017 Aug;162(8):2247-2256.
:
PMID: 28536674
Wang M, Yang F, Huang D, Huang Y, Zhang X, Wang C, Zhang S, Zhang R.Anti-Idiotypic Antibodies Specific to prM Monoantibody Prevent Antibody Dependent Enhancement of Dengue Virus Infection. Front Cell Infect Microbiol. 2017 May 9;7:157.
:
PMID: 28481883
Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA,Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, Subbarao K, Diehl SA, Kirkpatrick BD. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017 May 8;11(5):e0005584.
:
PMID: 28637753
Wong YH, Goh BC, Lim SY, Teo EW, Lim APC, Dedon PC, Hanson BJ, MacAry PA,Lescar J. Structural mimicry of the dengue virus envelope glycoprotein revealed by the crystallographic study of an idiotype-anti-idiotype Fab complex. J Virol. 2017 Jun 21. pii: JVI.00406-17.

 

 
BIC, JBTDRC, MGIMS
Sevagram, Wardha, Maharashtra - 442102, India
Guest   |   Sign Out